10:06 AM EST, 11/18/2024 (MT Newswires) -- Contineum Therapeutics ( CTNM ) said Monday the US Food and Drug Administration approved its investigational new drug application for PIPE-791 to treat chronic pain related to osteoarthritis and low back pain.

The phase 1b trial to potentially treat the two indications is expected to start in Q1 2025, the company said, adding it expects to enroll about 40 people at up to five sites.

Topline results from the trial are expected in early 2026, Contineum said.

Price: 16.50, Change: -0.71, Percent Change: -4.13